Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB1102 in Relapsed or Refractory AML or MDS
NCT02732184Phase 1Completed
- Sponsor
- Immedica
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of pegzilarginase in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Immedica. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started Aug 2016; status: completed.
02
Drugs
pegzilarginase
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02732184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02732184.